+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Polio - Pipeline Review, H1 2015

  • ID: 3266301
  • Report
  • April 2015
  • 63 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biological E. Limited
  • Codagenix, Inc.
  • Grifols, S.A.
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Sinovac Biotech Ltd.
  • MORE
Polio - Pipeline Review, H1 2015

Summary

This, ‘Polio - Pipeline Review, H1 2015’, provides an overview of the Polio’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polio, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polio and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polio
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Polio and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Polio pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Polio
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Polio pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Biological E. Limited
  • Codagenix, Inc.
  • Grifols, S.A.
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Sinovac Biotech Ltd.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Polio Overview
Therapeutics Development
Pipeline Products for Polio - Overview
Pipeline Products for Polio - Comparative Analysis
Polio - Therapeutics under Development by Companies
Polio - Therapeutics under Investigation by Universities/Institutes
Polio - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Polio - Products under Development by Companies
Polio - Products under Investigation by Universities/Institutes
Polio - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
Bharat Biotech International Limited
Biological E. Limited
Codagenix, Inc.
Grifols, S.A.
Panacea Biotec Limited
Sanofi Pasteur SA
Sentinext Therapeutics Sdn Bhd
Sinovac Biotech Ltd.
Polio - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPVGVI-3000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio (bivalent) virus like particle vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio (monovalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio [sabin] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio vaccine [types 1, 2, 3] (monovalent) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
poliomyelitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PR-5I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-073 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polio - Recent Pipeline Updates
Polio - Dormant Projects
Polio - Discontinued Products
Polio - Product Development Milestones
Featured News & Press Releases
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Polio, H1 2015
Number of Products under Development for Polio - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Polio - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015
Polio - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015
Polio - Pipeline by Bharat Biotech International Limited, H1 2015
Polio - Pipeline by Biological E. Limited, H1 2015
Polio - Pipeline by Codagenix, Inc., H1 2015
Polio - Pipeline by Grifols, S.A., H1 2015
Polio - Pipeline by Panacea Biotec Limited, H1 2015
Polio - Pipeline by Sanofi Pasteur SA, H1 2015
Polio - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2015
Polio - Pipeline by Sinovac Biotech Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Polio Therapeutics - Recent Pipeline Updates, H1 2015
Polio - Dormant Projects, H1 2015
Polio - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Polio, H1 2015
Number of Products under Development for Polio - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
Bharat Biotech International Limited
Biological E. Limited
Codagenix, Inc.
Grifols, S.A.
Panacea Biotec Limited
Sanofi Pasteur SA
Sentinext Therapeutics Sdn Bhd
Sinovac Biotech Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll